3-(2-{3-[2-(3,4-dimethoxyphenyl)acetylamino]benzoylamino}ethyl)piperidine-1-carboxylic acid tert-butyl ester | 1203719-36-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-{3-[2-(3,4-dimethoxyphenyl)acetylamino]benzoylamino}ethyl)piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 3-[2-[[3-[[2-(3,4-dimethoxyphenyl)acetyl]amino]benzoyl]amino]ethyl]piperidine-1-carboxylate
• CAS: 1203719-36-1
• 化学式: C₂₉H₃₉N₃O₆
• 分子量: 525.645
• InChiKey: KCNUPZVTZNHYMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  38
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(2-{3-[2-(3,4-dimethoxyphenyl)acetylamino]benzoylamino}ethyl)piperidine-1-carboxylic acid tert-butyl ester 在 盐酸 、 甲醇 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以45%的产率得到3-[2-(3,4-dimethoxyphenyl)acetylamino]-N-(2-piperidin-3-ylethyl)benzamide
  参考文献：
  名称：

  Hit to Lead Account of the Discovery of Bisbenzamide and Related Ureidobenzamide Inhibitors of Rho Kinase

  摘要：

  A highly selective series of bisbenzamide inhibitors of Rho-associated coiled-coil forming protein kinase (ROCK) and a related ureidoberizamide series, both identified by high throughput screening (HTS), are described. Details of the lilt validation and lead generation process, Including structure-activity relationship (SAR) studies, a selectivity assessment, target-independent profiling (TIP) results, and an analysis of functional activity using a rat aortic ring assay are discussed.

  DOI：

  10.1021/jm9014263
• 作为产物：
  描述：

  2-(N-Boc-3-哌啶基)乙胺 、 3-[2-(3,4-dimethoxyphenyl)acetylamino]benzoic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以84%的产率得到3-(2-{3-[2-(3,4-dimethoxyphenyl)acetylamino]benzoylamino}ethyl)piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Hit to Lead Account of the Discovery of Bisbenzamide and Related Ureidobenzamide Inhibitors of Rho Kinase

  摘要：

  A highly selective series of bisbenzamide inhibitors of Rho-associated coiled-coil forming protein kinase (ROCK) and a related ureidoberizamide series, both identified by high throughput screening (HTS), are described. Details of the lilt validation and lead generation process, Including structure-activity relationship (SAR) studies, a selectivity assessment, target-independent profiling (TIP) results, and an analysis of functional activity using a rat aortic ring assay are discussed.

  DOI：

  10.1021/jm9014263